Okla. Stat. tit. 63, § 63-5026
This is the official text of Okla. Stat. tit. 63, § 63-5026, part of Oklahoma’s Stat. tit. 63, — part of the compiled statutory law of Oklahoma, published by the state as "Stat. tit. 63,." Browse the sections below, each linked to its official government source.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
Medicaid prescription drug program – Definition of
Official statutory text
phenylketonuria.
A. The Oklahoma Health Care Authority Board shall, in
administering the Medicaid prescription drug program, utilize the
following definition for "phenylketonuria" to mean: An inborn error
of metabolism attributable to a deficiency of or a defect in
phenylalanine hydroxylase, the enzyme that catalyzes the conversion
of phenylalanine to tyrosine. The deficiency permits the
accumulation of phenylalanine and its metabolic products in the body
fluids. The deficiency can result in intellectual disabilities
(phenylpyruvic oligophrenia), neurologic manifestations (including
hyperkinesia, epilepsy, and microcephaly), light pigmentation, and
eczema. The disorder is transmitted as an autosomal recessive trait
and can be treated by administration of a diet low in phenylalanine.
B. The Oklahoma Health Care Authority Board shall promulgate
any rules necessary to effectuate the provisions of this section.
A. The Oklahoma Health Care Authority Board shall, in
administering the Medicaid prescription drug program, utilize the
following definition for "phenylketonuria" to mean: An inborn error
of metabolism attributable to a deficiency of or a defect in
phenylalanine hydroxylase, the enzyme that catalyzes the conversion
of phenylalanine to tyrosine. The deficiency permits the
accumulation of phenylalanine and its metabolic products in the body
fluids. The deficiency can result in intellectual disabilities
(phenylpyruvic oligophrenia), neurologic manifestations (including
hyperkinesia, epilepsy, and microcephaly), light pigmentation, and
eczema. The disorder is transmitted as an autosomal recessive trait
and can be treated by administration of a diet low in phenylalanine.
B. The Oklahoma Health Care Authority Board shall promulgate
any rules necessary to effectuate the provisions of this section.
Status: in_force · Read it on the official government site
Need a lawyer in Oklahoma?
Find a Oklahoma lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.